Condition
Ulcerative Colitis
Clear, practical articles to help you understand Ulcerative Colitis symptoms, medications, flares, nutrition, and everyday disease management. Browse our articles below.
Does Aetna Cover Tremfya for Ulcerative Colitis?
What Aetna requires before it pays for Tremfya in ulcerative colitis.
Does Aetna Cover Skyrizi for Ulcerative Colitis?
What Aetna requires before it pays for Skyrizi in ulcerative colitis.
Does Aetna Cover Omvoh for Ulcerative Colitis?
What Aetna's Omvoh prior authorization and step therapy really require for UC.
Does Aetna Cover Entyvio for Ulcerative Colitis?
What Aetna's policy requires before it approves Entyvio for UC.
Tremfya vs Stelara for Ulcerative Colitis: Key Comparison
Tremfya and Stelara are two Johnson & Johnson IL-23 pathway biologics for moderate-to-severe ulcerative colitis. Stelara has been the established UC option since its UNIFI-based approval, while Tremfya received UC approval in 2024 based on the QUASAR and ASTRO trials. The drugs differ in mechanism. Tremfya selectively blocks IL-23 through p19, while Stelara blocks both IL-12 and IL-23 through p40. For Crohn's, GALAXI 2 and 3 demonstrated Tremfya's superiority over Stelara on endoscopic endpoints. UC patients often ask whether similar logic applies to their disease. This guide walks through the tremfya vs stelara ulcerative colitis decision.
Tremfya vs Remicade for Ulcerative Colitis: Patient Guide
Tremfya and Remicade take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Remicade is the original anti-TNF for UC, with an efficacy record stretching back to ACT-1 and ACT-2 in the mid-2000s. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, offering both IV and fully subcutaneous induction pathways. UC patients commonly weigh these two drugs when choosing a first biologic or switching after loss of response. This guide walks through the tremfya vs remicade ulcerative colitis decision.
Tremfya vs Omvoh for Ulcerative Colitis: Which to Choose?
Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis, both newly approved for the indication. Omvoh gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2. Tremfya gained UC approval in September 2024 based on QUASAR and ASTRO. Patients comparing these two within-class UC options often weigh induction flexibility, urgency outcomes, and maintenance dosing. This guide walks through the tremfya vs omvoh ulcerative colitis comparison.
Tremfya vs Humira for Ulcerative Colitis: Which Is Right?
Tremfya and Humira are two biologics for moderate-to-severe ulcerative colitis that take fundamentally different mechanistic approaches. Humira is the established anti-TNF with more than a decade of UC experience. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, which uniquely offers both subcutaneous and intravenous induction pathways. UC patients choosing between these drugs weigh mechanism, administration flexibility, and long-term safety. This guide walks through the tremfya vs humira ulcerative colitis decision.
Tremfya vs Entyvio for Ulcerative Colitis: A Comparison
Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the tremfya vs entyvio ulcerative colitis comparison.
Stelara vs Remicade for Ulcerative Colitis: A Comparison
Stelara and Remicade are two commonly used biologics for moderate-to-severe ulcerative colitis, and both start with an intravenous infusion. Beyond that shared starting point, they work differently, have different safety profiles, and come with very different maintenance schedules. Patients typically weigh them when starting a first biologic, switching after anti-TNF failure, or looking at long-term infection risk. This guide walks through the evidence UC patients need to make an informed stelara vs remicade ulcerative colitis decision with their gastroenterologist.
Stelara vs Humira for Ulcerative Colitis: Key Differences
Stelara and Humira are two of the most common biologics discussed when ulcerative colitis patients are starting a first biologic or looking for a next step after losing response. Humira is a long-established anti-TNF. Stelara is an IL-12/23 blocker that arrived in UC much more recently. They work through different immune pathways, come with different dosing schedules, and differ meaningfully on safety. This guide walks through the evidence UC patients need to make an informed stelara vs humira ulcerative colitis decision with their gastroenterologist.
Skyrizi vs Tremfya for Ulcerative Colitis: Comparing IL-23s
Skyrizi and Tremfya are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis. Skyrizi gained UC approval in June 2024 based on INSPIRE and COMMAND. Tremfya gained UC approval in September 2024 based on QUASAR and ASTRO. Patients comparing these two within-class UC options often weigh induction flexibility, maintenance dosing, and trial design. This guide walks through the skyrizi vs tremfya ulcerative colitis comparison.